Figure 11.
A homozygous Acer null mutant rescues STM in flies expressing C99V717Iand Aβ42. Percentage of CIs and MIs are shown as labeled for (A) elav-GAL4C155>UAS-C99V717I and (B) elav-GAL4C155>UAS-Aβ42 flies. CIs were calculated by dividing the time a male spent in courtship to a total given time. Trainer and tester females: –, none; m, mated female. Box-and-whisker plots for CI show 10th, 25th, 75th, and 90th percentiles and mean (+). MIs were calculated as [100 [1 – (CI with training/mean of CI without training)]. Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used for statistical comparisons (N ≥ 20 per genotype per condition). elav-GAL4C155>UAS-C99V717I flies treated with captopril as well as those carrying an Acer null mutant +/− captopril had significantly higher MIs when compared with no drug condition (p = 0.0005, p < 0.0001, and p < 0.0001, respectively). A similar effect was observed in Aβ42 flies treated with captopril or in flies carrying an Acer null mutant +/− captopril (p = 0.0001, p < 0.0001, and p = 0.0001, respectively). Data are shown as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n.s., not significant.